Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation

Makoto Yoshimitsu, Ryuji Tanosaki, Koji Kato, Takashi Ishida, Ilseung Choi, Yoshifusa Takatsuka, Takahiro Fukuda, Tetsuya Eto, Michihiro Hidaka, Naoyuki Uchida, Toshihiro Miyamoto, Yasuhiro Nakashima, Yukiyoshi Moriuchi, Koji Nagafuji, Yasuhiko Miyazaki, Tatsuo Ichinohe, Minoko Takanashi, Yoshiko Atsuta, Atae Utsunomiya

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-specific comorbidity index [HCT-CI]/modified European Group for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematologic malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict nonrelapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 versus HCT-CI 1 to 3 and HCT-CI 0 versus HCT-CI ≥ 4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor-recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0%, 27.7%, and 44.4%, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients.

Original languageEnglish
JournalBiology of Blood and Marrow Transplantation
DOIs
Publication statusAccepted/In press - 2017 Jan 1

Fingerprint

Adult T Cell Leukemia Lymphoma
Hematopoietic Stem Cell Transplantation
Cell Transplantation
Mortality
Comorbidity
Hematopoietic System
Hematologic Neoplasms

Keywords

  • Adult T cell leukemia/lymphoma
  • Allogeneic hematopoietic cell transplantation
  • Comorbidities
  • Hematologic malignancies
  • Mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. / Yoshimitsu, Makoto; Tanosaki, Ryuji; Kato, Koji; Ishida, Takashi; Choi, Ilseung; Takatsuka, Yoshifusa; Fukuda, Takahiro; Eto, Tetsuya; Hidaka, Michihiro; Uchida, Naoyuki; Miyamoto, Toshihiro; Nakashima, Yasuhiro; Moriuchi, Yukiyoshi; Nagafuji, Koji; Miyazaki, Yasuhiko; Ichinohe, Tatsuo; Takanashi, Minoko; Atsuta, Yoshiko; Utsunomiya, Atae.

In: Biology of Blood and Marrow Transplantation, 01.01.2017.

Research output: Contribution to journalArticle

Yoshimitsu, M, Tanosaki, R, Kato, K, Ishida, T, Choi, I, Takatsuka, Y, Fukuda, T, Eto, T, Hidaka, M, Uchida, N, Miyamoto, T, Nakashima, Y, Moriuchi, Y, Nagafuji, K, Miyazaki, Y, Ichinohe, T, Takanashi, M, Atsuta, Y & Utsunomiya, A 2017, 'Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2017.11.005
Yoshimitsu, Makoto ; Tanosaki, Ryuji ; Kato, Koji ; Ishida, Takashi ; Choi, Ilseung ; Takatsuka, Yoshifusa ; Fukuda, Takahiro ; Eto, Tetsuya ; Hidaka, Michihiro ; Uchida, Naoyuki ; Miyamoto, Toshihiro ; Nakashima, Yasuhiro ; Moriuchi, Yukiyoshi ; Nagafuji, Koji ; Miyazaki, Yasuhiko ; Ichinohe, Tatsuo ; Takanashi, Minoko ; Atsuta, Yoshiko ; Utsunomiya, Atae. / Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2017.
@article{913042ea3736474285bb10639824f49d,
title = "Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation",
abstract = "Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-specific comorbidity index [HCT-CI]/modified European Group for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematologic malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict nonrelapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 versus HCT-CI 1 to 3 and HCT-CI 0 versus HCT-CI ≥ 4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor-recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0{\%}, 27.7{\%}, and 44.4{\%}, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients.",
keywords = "Adult T cell leukemia/lymphoma, Allogeneic hematopoietic cell transplantation, Comorbidities, Hematologic malignancies, Mortality",
author = "Makoto Yoshimitsu and Ryuji Tanosaki and Koji Kato and Takashi Ishida and Ilseung Choi and Yoshifusa Takatsuka and Takahiro Fukuda and Tetsuya Eto and Michihiro Hidaka and Naoyuki Uchida and Toshihiro Miyamoto and Yasuhiro Nakashima and Yukiyoshi Moriuchi and Koji Nagafuji and Yasuhiko Miyazaki and Tatsuo Ichinohe and Minoko Takanashi and Yoshiko Atsuta and Atae Utsunomiya",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2017.11.005",
language = "English",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation

AU - Yoshimitsu, Makoto

AU - Tanosaki, Ryuji

AU - Kato, Koji

AU - Ishida, Takashi

AU - Choi, Ilseung

AU - Takatsuka, Yoshifusa

AU - Fukuda, Takahiro

AU - Eto, Tetsuya

AU - Hidaka, Michihiro

AU - Uchida, Naoyuki

AU - Miyamoto, Toshihiro

AU - Nakashima, Yasuhiro

AU - Moriuchi, Yukiyoshi

AU - Nagafuji, Koji

AU - Miyazaki, Yasuhiko

AU - Ichinohe, Tatsuo

AU - Takanashi, Minoko

AU - Atsuta, Yoshiko

AU - Utsunomiya, Atae

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-specific comorbidity index [HCT-CI]/modified European Group for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematologic malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict nonrelapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 versus HCT-CI 1 to 3 and HCT-CI 0 versus HCT-CI ≥ 4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor-recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0%, 27.7%, and 44.4%, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients.

AB - Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-specific comorbidity index [HCT-CI]/modified European Group for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematologic malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict nonrelapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 versus HCT-CI 1 to 3 and HCT-CI 0 versus HCT-CI ≥ 4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor-recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0%, 27.7%, and 44.4%, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients.

KW - Adult T cell leukemia/lymphoma

KW - Allogeneic hematopoietic cell transplantation

KW - Comorbidities

KW - Hematologic malignancies

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=85039424663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039424663&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2017.11.005

DO - 10.1016/j.bbmt.2017.11.005

M3 - Article

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -